Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) and Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.
Profitability
This table compares Karyopharm Therapeutics and Milestone Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Karyopharm Therapeutics | -153.28% | N/A | -145.18% |
| Milestone Pharmaceuticals | N/A | -288.33% | -58.27% |
Analyst Ratings
This is a breakdown of current ratings and price targets for Karyopharm Therapeutics and Milestone Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Karyopharm Therapeutics | 1 | 2 | 3 | 1 | 2.57 |
| Milestone Pharmaceuticals | 1 | 1 | 4 | 1 | 2.71 |
Valuation and Earnings
This table compares Karyopharm Therapeutics and Milestone Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Karyopharm Therapeutics | $146.07 million | 0.19 | -$196.04 million | ($13.09) | -0.09 |
| Milestone Pharmaceuticals | $1.55 million | 65.86 | -$63.06 million | ($0.69) | -1.19 |
Milestone Pharmaceuticals has lower revenue, but higher earnings than Karyopharm Therapeutics. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk & Volatility
Karyopharm Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.
Summary
Milestone Pharmaceuticals beats Karyopharm Therapeutics on 10 of the 14 factors compared between the two stocks.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
